|Bid||5.78 x 1000|
|Ask||7.21 x 300|
|Day's Range||5.92 - 6.14|
|52 Week Range||5.70 - 14.51|
|PE Ratio (TTM)||-3.07|
|Earnings Date||Apr 13, 2016 - Apr 14, 2016|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||20.67|
Advaxis, Inc. , a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products, today announced three abstracts were selected for presentation at the third annual CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference: Translating Science into Survival.
Advaxis, Inc. , a late-stage biotechnology company focused on the discovery, development and commercialization of immunotherapy products based on its proprietary Lm-based antigen delivery system, today announced presentation of clinical data and a publication reviewing the mechanism of action via two prestigious oncology forums for its lead immunotherapy candidate, axalimogene filolisbac.
Cancer immunotherapy developer Advaxis Inc said on Thursday Daniel O'Connor stepped down from his position as the company's chief executive and its board. Anthony Lombardo will immediately assume the role ...